Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03147287 · ClinicalTrials.gov registry record · Phase 2
Palbociclib After CDK and Endocrine Therapy (PACE)
A Phase 2 study of Metastatic Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT03147287 is a Phase 2 study of Metastatic Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 220 participants, roughly in line with the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT03147287, a Phase 2 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: -Fulvestrant -Fulvestrant with Palbociclib -Fulvestrant with Palbociclib and Avelumab
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Palbociclib
- DRUG Avelumab
Study Locations (20)
Massachusetts
- Boston Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Dana-Farber at St. Elizabeth's Medical Center - Brighton
- DF/BWCC at Milford Regional Medical Center - Milford
- DF/BWCC in clinical affiliation with South Shore Hospital - South Weymouth
Kansas
- The University of Kansas Cancer Center - North - Kansas City
- The University of Kansas Cancer Center - Overland Park - Overland Park
- The University of Kansas Cancer Center - Westwood
Missouri
- The University of Kansas Cancer Center - Lee's Summit - Lee's Summit
- Washington University - St Louis
Florida
- University of Miami - Miami
Georgia
- Emory University - Winship Cancer Institute - Atlanta
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University - Indianapolis
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03147287
The ClinicalTrials.gov registry entry for NCT03147287 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT03147287 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT03147287 about?
NCT03147287 is a clinical study titled "Palbociclib After CDK and Endocrine Therapy (PACE)". This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: -Fulvestrant -Fulvestrant with Palbociclib -Fulvestrant with Palbociclib and Avelumab
What is the current status of trial NCT03147287?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2017-09-05. Estimated completion is 2026-06-30.
What conditions does trial NCT03147287 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT03147287?
The interventions under investigation include: Fulvestrant (DRUG), Palbociclib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT03147287?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03147287 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.